Discover CME, tools, and guideline-focused education to improve your knowledge - and patient outcomes.
Chairperson's Perspective: Innovative Approaches to IBS-C: Personalized Treatment for Better Outcomes
Darren Brenner, MD
Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
Neal Shore, MD, FACS
Sarah Psutka, MD, MS
What’s New In Glaucoma?
Paul Petrakos, DO, MS
Justin Schweitzer, OD, FAAO
I. Paul Singh, MD
Sarah H. Van Tassel, MD
New Strategies for Individualizing Treatment in DME
Luis A. Gonzalez, MD, MPH
Jeremiah Brown Jr., MD, MS, FASRS
SunRISe-1: 1-Year Durability and Patient-Reported Outcomes Results
Treatment Advances in Generalized Myasthenia Gravis: A Pathophysiology-Driven Framework Leveraging FcRn Therapeutics
Vera Bril, MD
Neelam Goyal, MD
Revolutionizing Diagnostic Precision: AI-Driven Approaches in Digital Pathology and HER2 Expression
Marilyn Yuanxin Ma Bui, MD, PhD
Anne Vincent-Salomon, MD
New Frontiers in MG: How FcRn Antagonists Are Changing MG Therapy
Nicholas J. Silvestri, MD
Non-CF Bronchiectasis: How Radiologists Can Drive Better Outcomes
Robert D. Suh, MD
Lea Azour, MD
Ashwin Basavaraj, MD
Acromegaly Care: Individualized Diagnosis and Management Strategies
July 13, 2025
San Francisco, California
A Scientific Look at FcRn Antagonists: Mechanisms of Action Explained
Ocular to Generalized MG: How and Why the Disease Evolves
Hans Katzberg, MD
Living with gMG: Navigating Personal, Professional, and Mental Health Challenges
Autoantibodies Explained: Anti-AChR, Anti-MuSK, and Their Diagnostic Role
Advancing Myasthenia Gravis (MG) Treatment Through Guideline Updates and Emerging Therapies
October 30, 2025
First Results From Cohort 4 of the SunRISe-1 Trial
Trial in Progress: Phase 3 MoonRISe-3 Study
Precision Medicine for gMG: Tailoring Treatments Based on Patient Profiles
Diagnostic Advances in gMG: Effective Tools and Techniques
Collaborative Insights to Solve the Puzzle of Bladder Cancer
Daniel P. Petrylak, MD
Elizabeth R. Plimack, MD, MS, FASCO
Evan Y. Yu, MD
Managing Side Effects in FcRn Therapy: Best Practices for gMG
Preventing Myasthenic Crisis: Early Signs and Critical Interventions
Chairperson’s Perspective: Treating At-Risk MASH: What Are You Waiting For?
Mazen Noureddin, MD, MHSc
What’s New in Glaucoma Therapy?
What’s New in Subconjunctival MIBS
What’s New in Suprachoroidal MIGS?
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.